CN119136804A - 包含卡利拉嗪或其盐的储库系统 - Google Patents

包含卡利拉嗪或其盐的储库系统 Download PDF

Info

Publication number
CN119136804A
CN119136804A CN202380028161.9A CN202380028161A CN119136804A CN 119136804 A CN119136804 A CN 119136804A CN 202380028161 A CN202380028161 A CN 202380028161A CN 119136804 A CN119136804 A CN 119136804A
Authority
CN
China
Prior art keywords
composition
calicheazine
acid
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380028161.9A
Other languages
English (en)
Chinese (zh)
Inventor
塞·鲁比诺夫
埃胡德·马罗姆
安娜·格平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mapi Pharma Ltd
Original Assignee
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd
Publication of CN119136804A publication Critical patent/CN119136804A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202380028161.9A 2022-03-17 2023-02-14 包含卡利拉嗪或其盐的储库系统 Pending CN119136804A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263320706P 2022-03-17 2022-03-17
US63/320,706 2022-03-17
PCT/IL2023/050150 WO2023175598A1 (en) 2022-03-17 2023-02-14 Depot systems comprising cariprazine or salts thereof

Publications (1)

Publication Number Publication Date
CN119136804A true CN119136804A (zh) 2024-12-13

Family

ID=88022782

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380028161.9A Pending CN119136804A (zh) 2022-03-17 2023-02-14 包含卡利拉嗪或其盐的储库系统

Country Status (9)

Country Link
US (2) US11931357B2 (cg-RX-API-DMAC7.html)
EP (1) EP4493274A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025509390A (cg-RX-API-DMAC7.html)
CN (1) CN119136804A (cg-RX-API-DMAC7.html)
AU (1) AU2023234747A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244202A1 (cg-RX-API-DMAC7.html)
IL (1) IL315074A (cg-RX-API-DMAC7.html)
MX (1) MX2024011063A (cg-RX-API-DMAC7.html)
WO (1) WO2023175598A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12514908B2 (en) 2021-07-05 2026-01-06 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CA3244202A1 (en) * 2022-03-17 2023-09-21 Mapi Pharma Ltd. DEPOSIT SYSTEMS INCLUDING CARIPRAZINE OR SALTS THEREOF
US20230372331A1 (en) * 2022-05-18 2023-11-23 Anxo Pharmaceutical Co., Ltd. Pharmaceutical composition
CN119424341A (zh) * 2023-08-02 2025-02-14 珠海市华海康医药科技有限责任公司 一种注射用药物缓释微球及其制备方法
CN117137864A (zh) * 2023-11-01 2023-12-01 山东则正医药技术有限公司 一种卡利拉嗪原位凝胶制剂及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
ES2653852T3 (es) * 2007-08-03 2018-02-09 Richter Gedeon Nyrt. Composiciones farmacéuticas que contienen ligandos del receptor de dopamina y procedimientos de tratamiento usando ligandos del receptor de dopamina
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
AU2017319728B2 (en) * 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
CN108261394B (zh) 2017-01-04 2022-03-04 广东东阳光药业有限公司 一种盐酸卡利拉嗪注射制剂及其制备方法和用途
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
US11344503B2 (en) * 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations
WO2022003662A1 (en) * 2020-06-29 2022-01-06 Mapi Pharma Ltd. Low burst-release liraglutide depot systems
CA3244202A1 (en) * 2022-03-17 2023-09-21 Mapi Pharma Ltd. DEPOSIT SYSTEMS INCLUDING CARIPRAZINE OR SALTS THEREOF

Also Published As

Publication number Publication date
CA3244202A1 (en) 2023-09-21
MX2024011063A (es) 2024-09-23
JP2025509390A (ja) 2025-04-11
AU2023234747A1 (en) 2024-09-12
US20230293515A1 (en) 2023-09-21
WO2023175598A1 (en) 2023-09-21
EP4493274A4 (en) 2026-03-18
EP4493274A1 (en) 2025-01-22
US12251380B2 (en) 2025-03-18
IL315074A (en) 2024-10-01
US20240238280A1 (en) 2024-07-18
US11931357B2 (en) 2024-03-19

Similar Documents

Publication Publication Date Title
US11931357B2 (en) Depot systems comprising Cariprazine or salts thereof
WO2009060473A2 (en) Injectable compositions, processes and uses thereof
JP2010505819A (ja) デポ型注射剤組成物とその調製方法
US10058504B2 (en) Methods for the preparation of injectable depot compositions
ES2277682T3 (es) Formulacion de delavirdina en comprimido.
US10881605B2 (en) Methods for the preparation of injectable depot compositions
CN106344521B (zh) 一种高载药量可生物降解布比卡因微球的制备及其应用
US10558394B2 (en) Injectable flowable composition comprising buprenorphine
CN101854922A (zh) 用于减轻、预防或治疗疼痛和炎症的具有不同释放曲线的长效制剂
CN1468090A (zh) 缓释药物制剂及其施用方法
AU2004264885A1 (en) Aripiprazole and haloperidol pamoate salts
JP2024526279A (ja) セマグルチドデポー系及びその使用
WO2013161830A1 (ja) 注射製剤
US20230256058A1 (en) Low burst-release liraglutide depot systems
WO2006032202A1 (fr) Formulation à libération lente et prolongée contenant un agoniste du récepteur de la dopamine et son procédé de préparation
EP1585519A1 (en) High concentration formulations of opioids and opioid derivatives
JP6250005B2 (ja) 制御放出製剤
HK40116297A (en) Depot systems comprising cariprazine or salts thereof
EP3720420B1 (en) Injectable long-acting local anesthetic semi-solid gel formulations
CN1857220B (zh) 一种抗结核病药物缓释剂
TW202529795A (zh) 新穎組成物
TW202435885A (zh) 卡利拉嗪(Cariprazine)之長效性注射用(LAI)組合物
JP2025515960A (ja) 医薬組成物
KR20250161987A (ko) 로피바케인 및 비스테로이드성 항염증제를 포함하는 서방형 미립구 및 이의 제조방법
HK40104236A (en) Semaglutide depot systems and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40116297

Country of ref document: HK